In vivo binding of a tau imaging probe, [¹¹ C]PBB3, in patients with progressive supranuclear palsy.

ABSTRACT:

Background

[¹¹ C]pyridinyl-butadienyl-benzothiazole 3 is a PET imaging agent designed for capturing pathological tau aggregates in diverse neurodegenerative disorders, and would be of clinical utility for neuropathological investigations of PSP.

Objectives

To explore the usefulness of [¹¹ C]pyridinyl-butadienyl-benzothiazole 3/PET in assessing characteristic distributions of tau pathologies and their association with clinical symptoms in the brains of living PSP patients.

Methods

We assessed 13 PSP patients and 13 age-matched healthy control subjects. Individuals negative for amyloid β PET with [¹¹ C]Pittsburgh compound B underwent clinical scoring, MR scans, and [¹¹ C]pyridinyl-butadienyl-benzothiazole 3/PET.

Results

SUBMITTER: Endo H 

PROVIDER: S-EPMC6593859 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature